Skip to main content
Top

17-06-2024 | Prostatectomy | Original Article

Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy

Authors: Takeru Fujimoto, Takayuki Goto, Rihito Aizawa, Takashi Ogata, Kiyonao Nakamura, Takayuki Sumiyoshi, Yuki Kita, Kimihiko Masui, Takeshi Sano, Atsuro Sawada, Ryoichi Saito, Shusuke Akamatsu, Takashi Mizowaki, Takashi Kobayashi

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

Background

It remains unclear which patients with biochemical recurrence after prostatectomy are most suitable for salvage radiotherapy. We evaluated the parameters related to outcomes.

Methods

We retrospectively evaluated patients who underwent salvage therapy for biochemical recurrence after prostatectomy between 2005 and 2019. This study aimed to evaluate biochemical recurrence-free survival (bRFS) after salvage radiotherapy and elucidate the parameters associated with bRFS. The bRFS rate was calculated using the Kaplan–Meier method, and the parameters associated with bRFS were evaluated using Cox regression analysis.

Results

This study included 67 patients treated with salvage radiotherapy with a median age of 67 years at salvage radiotherapy. The median follow-up period after salvage radiotherapy was 7.3 years. The 5-year bRFS rate following salvage radiotherapy was 47.1%. Univariate analysis showed that PSA doubling time < 6 months, positive surgical margin, and pathological Gleason score ≥ 8 were significantly associated with shorter bRFS (p < 0.001, p = 0.036, p = 0.047, respectively). Multivariable analysis showed that a PSA doubling time < 6 months and positive surgical margins were significantly associated with shorter bRFS (p = 0.001 and p = 0.018, respectively). No serious adverse events were observed.

Conclusions

In our hospital, approximately half of the patients are under long-term control with salvage radiotherapy. A PSA doubling time of < 6 months and positive surgical margins were suggested to be associated with poor outcomes of salvage radiotherapy.
Literature
10.
go back to reference Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545. https://doi.org/10.1016/j.juro.2006.10.097CrossRefPubMed Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177(2):540–545. https://​doi.​org/​10.​1016/​j.​juro.​2006.​10.​097CrossRefPubMed
Metadata
Title
Clinical factors predicting the outcome of salvage radiotherapy for patients with biochemical recurrence after radical prostatectomy
Authors
Takeru Fujimoto
Takayuki Goto
Rihito Aizawa
Takashi Ogata
Kiyonao Nakamura
Takayuki Sumiyoshi
Yuki Kita
Kimihiko Masui
Takeshi Sano
Atsuro Sawada
Ryoichi Saito
Shusuke Akamatsu
Takashi Mizowaki
Takashi Kobayashi
Publication date
17-06-2024
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-024-02571-7

2024 ASCO Annual Meeting Coverage

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare